

Amgen Inc.
Law Department
51 University Street
Seattle, WA 98101

Telephone: 206-265-4071
Facsimile: 206-233-0644
e-mail: Sprunges@amgen.com

FAX MESSAGE - PLEASE DELIVER IMMEDIATELY

Send to: **Examiner William Moore** FAX: (703) 746-3169
Art Unit 1652
U.S. Patent and Trademark Office

From: **Suzanne A. Sprunger** Date: **30 October 2003**

No. of pages including this page: 8

Re: Application Ser. No. 09/634,252

AS WE DISCUSSED ON TUESDAY 28 OCTOBER.
THANK YOU!
— SA8

If transmission problems occur contact Suzanne Sprunger at 206-265-4071.

Form II → case is allowable

Wash,
this is Applicant's
FAX following your
suggestion in Tuesday's
interview.
Claims 34 → 36 are
now canceled and a new
claim 50 appears
— B.M.

CONFIDENTIALITY NOTICE: This communication (including any accompanying page(s)) is intended solely for the use of the individual or entity named above and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, you are hereby notified that any copying, distribution or other unauthorized use of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service. Thank you.

Application No. 09/634,252
DRAFT Amendment After Final dated 30 Oct 2003

2862-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No: 09/634,252
Applicants: Douglas P. CERRETTI
Filing Date: August 7, 2000
Title: METALLOPROTEASE-DISINTEGRIN ADAM23 (SVPH3-17)
NUCLEIC ACIDS
Docket No.: 2862-US
Examiner: William MOORE
Art Unit: 1652

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DRAFT AMENDMENT AND RESPONSE AFTER FINAL REJECTION

Responsive to the Final Office Action mailed May 29, 2003 ("the Office Action"), Applicants respectfully request the Examiner enter the following amendments in the above identified application:

Listing of Claims begins on page 2 of this paper.

Remarks begin on page 6 of this paper.